Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Target CAR t cells take on tough blood cancers

NCT ID NCT07166419

Recruiting now Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells by targeting three proteins (CD19, CD20, and CD22). The main goals are to find the safest dose and check for side effects in up to 24 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell chronic lymphocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive indolent B-cell non-Hodgkin lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive lymphoblastic lymphoma non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma refractory malignant neoplasm refractory precursor T-lymphoblastic lymphoma/leukemia Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLAST PHASE CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA RECURRENT CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE RECURRENT INDOLENT NON-HODGKIN LYMPHOMA RECURRENT LYMPHOBLASTIC LYMPHOMA RECURRENT NON-HODGKIN LYMPHOMA RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA REFRACTORY LYMPHOBLASTIC LYMPHOMA REFRACTORY NON-HODGKIN LYMPHOMA REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact